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We assessed the levels ofarsenic in drilledwells in Finland and studied the association ofarsenic
exposurewith theriskofbladderandkidneycancers. Thestudypersons were selected fom a reg-
ister-based cohort ofall Finns who had lived at an address outside the municipal d -water
system during 1967-1980 (n = 144,627). Thefinalstudypopulation consistedof61 bladder can-
cer cases and 49 kidney cancer cases diagnosed between 1981 and 1995, as well as an age- and
sex-balanced random sample of275 subjects (reference cohort). Water samples were obtained
from thewells usedbythe studypopulation atleast during 1967-1980. The total arsencconcen-
trations in thewells ofthe reference cohort were low (median = 0.1 pgIL; maximum =64 pg/L),
and 1%/ exceeded 10 pg/L. Arsenic exposure was estimated as arsenic concentrationin the well,
dailydose, andcumutiv doseofarsenic. Noneoftheexposuireindicatorswas st ll signif-
icantly associated with the risk of kddney cancer. Bladder cancer tended to be associted with
arsenic concentration and dailydoseduring the thirdto ninthyears prior to the cancer diagnosis;
the riskratios forarsnic concentration categories 0.14.5 and 0.5 pWLrelative to the category
with c 0.1 pg/Lwe 1.53 [95% coniden interval (CI), 0.75-3.09] nd 2.4 (CI, 1.1-5.37),
respectively. In spite of very low exposure levels, we found some evidence of an association
bewnarsenic and bladder cancer risk Morestudies areneeded to confirm thepossible associa-
tionbetweenarsenicandbladdercancerriakatsuchlowexposure levels. Keyword arsenic, blad-
der cancer, drinking water, kidney cancer, rural, urinary organ cancers, well water. Environ
Heal Pperet 107:705-710 (1999). [Online 27July 1999]
htp://ehpneti.niebs.nib.gov/docs/l999I107p705-710kuraidoabstrac.htnl
Natural mineral deposits containing
arsenic may result in elevated levels of
arsenic in ground water. The World Health
Organization (WHO) classifies inorganic
arsenic as a human carcinogen; chronic
ingestion is associated with skin cancer and
inhalation is associated with lung cancer (1).
Arsenic concentrations in noncontaminated
drinking water are usually below 3 pg/L
(1-4). The present WHO drinking-water
guideline value of10 pg/L (4) is based main-
ly on epidemiologic studies on arsenic expo-
sure and skin cancer inTaiwan.
Epidemiologic studies based on high
arsenic exposure in Taiwan (5-11), Argentina
(12,13), Japan (14,15), and Chile (16) sug-
gest an increased risk ofcancer ofthe urinary
organs. The lowest arsenic exposure levels
associatedwith detrimental health effects have
been reported in a case-control study in the
United States in which the arsenic concentra-
tions in drinking water ranged from 0.5 to
180 pg/L (17). In that study, no overall asso-
ciation was found between arsenic exposure
and cancer risk, but arsenic and cigarette
smokingtended to have asynergisticeffect on
the riskofbladder cancer.
As much as 12-14% ofthe Finnish popu-
lation live outside areas with municipal water
supply and use privatewells (18). Waterqual-
ity of private wells is seldom monitored.
Concentrations ofarsenic measured in a rural
town in central Finland were up to 100 times
higher than drinking-water quality guideline
values (19). According to geologic surveys,
there are several other areas in Finland that
are prone to high arsenic concentrations (20),
but no countrywide surveyon arsenicconcen-
trations in well water has been carried out.
The aims ofthe present study were to deter-
mine whether arsenic exposure from well
water is associated with increased riskofblad-
der and kidney cancers and to assess the con-
centrations ofarsenic in drilled wells used for
drinkingwater in Finland.
Materials and Methods
Selection ofstudypopulation. Town quarters
or villages, in which less than 10% of the
population belong to the municipal drink-
ing-water system, were identified based on
the 1985 Population Census file of the
Statistics Finland. The source population
was defined from the Population Registry as
144,627 persons born in 1900-1930 who
had lived in these areas at the same address
at least from 1967 to 1980 (Figure 1). The
year 1967 was chosen because it was the ear-
liest for which information on residency had
been recorded systematically.
During 1981-1995, 884 bladder cancer
cases and 644 kidney cancer cases were iden-
tified within the cohort through a record
link with the Finnish Cancer Registry.
Because there are plans to conduct similar
studies based on the same reference cohort for
stomach cancer and leukemia, a case-cohort
design was used (21). Random selection of
the reference cohort was stratified by single
birthyear (range 1900-1930) andsex (i.e., 62
strata). The number ofpersons selected to the
reference cohortwithin each stratum was four
times the highest number ofsite-specific can-
cer cases in that stratum (i.e., either kidney,
bladder, leukemia, or stomach cancer).
Altogether, 4,590 persons were selected in the
reference cohort.
Final study series. The current residents
at the addresses occupied bythe case and ref-
erent persons in 1967-1980 were contacted
initially either by the local health inspectors
or by mailed questionnaire. The following
questions were asked: Did the house have a
drilled well? When was the drilled well
established? Had the drilled well been used
as the primarysource ofdrinkingwater?
Because drilled wells have been reported
to contain essentially higher arsenic concen-
trations than other types ofwells (22), only
those addresses where drinking water from
drilled wells was consumed before the year
1981 were selected for further study (Table
1). The use ofthe drilled wells for drinking
water had started before 1981 but may have
continued until 1996. Local health inspec-
tors collected well-water samples from the
selected addresses of509 subjects.
Those 380 subjects (76% of cases and
74% of reference cohort eligible) for whom
arsenic exposure could be estimated (i.e., the
well-water samplewas available andwell water
had been used as drinkingwater) were indud-
ed in thefinal analysis (Table 1). Theexcluded
and induded subjects did not differ by vital
status (40%/52% alive), age (mean birth year
1917/1916), sex (42%/39% women), occupa-
tion (61%/64% farmers), or education
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(2%/5% with more than 9 years of educa-
tion). Sixty-one cases with bladder cancer and
49 with kidney cancer were included (includ-
ing 3 cases with cancer ofthe renal pelvis, 41
with unilateral kidney cancer, 1 with cancer in
both kidneys, and 4with cancer in an uniden-
tified site). The reference cohort consisted of
275 subjects (induding 3 subjects who devel-
oped bladder cancer and 1 subject who was
diagnosedwith kidneycancer).
Questionnaire. Information on residen-
tial history and drinking-water consumption
at the selected addresses and potential
100 0 100 200 300 Kilometers
confounders such as smoking, use of anal-
gesics and diuretics in the 1970s, education,
and occupation was collected using a ques-
tionnaire mailed to the study subjects (i.e.,
cases and referents who had lived at the
selected addresses during 1967-1980) or
their next of kin (Tables 2 and 3). Subjects
received the questionnaires before the water
sampling in 1996. In addition, information
on the present occupation (previous occupa-
tion for retired persons) and education was
obtained from the Population Censuses of
1970, 1975, and 1980.
A Bladder cancer
O Kidney cancer
O Reference cohort
Figure 1. Selection ofthe study population. (A) Location of the members of the cohort of 144,627 persons
who were born in 1900-1930 and had lived outside the area of a municipal water source at least for 13
years before 1980. (8) Location of the bladder cancer cases (n = 61), kidney cancer cases (n = 49), and
members ofthe reference cohort (n= 275).
Table 1. Selection ofthe study population.
Bladder cancera
No. %
Kidney cancera
No. %
Reference cohort
No. %
Number of persons eligible afterfirst contact 79 100 65 100 371b 100
Water sample available 68 86 58 89 313C 84
Drilled well water used as drinking water 61 77 49 75 275C 74
and water sample available (final study series)
Questionnaire available 52 66 49 75 240d 65
Both water sample and questionnaire available 42 53 36 55 183e 49
Arsenic measurements. The well-water
samples were collected between July and
November 1996. The samples were collected
in random order, blinded in regard to the
case-referent status. Each sample was filtered
through a 0.45-pm membrane filter and acid-
ifiedwith HNO3 at the sample site. The sam-
ples were sent to the laboratorywithin 2 days.
Total arsenic was determined by Perkin
Elmer Sciex Elan 6000 inductively coupled
plasma mass spectrometry (Perkin-Elmer,
Rotkreuz, Switzerland). The detection limit
for arsenic was 0.05 pg/L. The performance
ofthe analytical method was monitored con-
tinuously including certified reference mate-
rials within the analytical batches. Sixty-four
of the samples were analyzed twice. The
median coefficient ofvariation was 2.2%.
To evaluate the validity ofwater sampling,
two water samples were taken from 36 ran-
domly selectedwells at two different times (on
average 31 days apart; range 2 hr-88 days).
The arsenic concentrations in the original
samples and field duplicates were not signifi-
candy different (median ofthe absolute differ-
ence between two samples was 0.02 ig/L; p =
0.2 in theWilcoxon signed ranks test).
Estimates ofarsenic exposure. The
arsenic exposure for cases with cancer and
members of reference cohort was estimated
in two periods: from the third to ninth cal-
endar years (shorter latency) and from the
tenth or earliercalendar years (longer latency)
prior to the cancer diagnosis (or the respec-
tive year for referent persons).
The daily dose of arsenic from drinking
water was calculated from the arsenic con-
centration ofwell water and from the report-
ed consumption ofwell water in the 1970s.
If questionnaire data were not available, the
consumption of drinking water was set as
the mean from the reference cohort. Men
consumed on average 1.6 L/day (range
0.1-4.5 L/day) and women consumed 1.6
L/day (0.6-3.0 L/day) ofwell water. At two
addresses (one member of the reference
cohort and one kidney cancer case), water
samples from two drilled wells were avail-
able. In those cases, the higher arsenic con-
centration was included in the calculations
ofarsenic concentration and daily dose, and
actual use for cumulative exposure.
Consumption of well water started on
average in 1970 [standard deviation (SD) =
8 years] and stopped in 1990 (SD = 6 years).
The cumulative dose was defined as an inte-
gral of duration and intensity of arsenic
exposure from well water. The cumulative
dose for the shorter latency was calculated
from the beginning of the use ofwell water
until 2 years before the cancer diagnosis. For
the longer latency, the cumulative dose was
calculated until 10 years before the cancer
diagnosis. The arsenic concentration in
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aOne person had both kidney and bladder cancers and is included in both case series. bincludes three bladder cancer
cases and two kidney cancer cases. cIncludes three bladder cancer cases and one kidney cancer case. dincludes two
bladder cancer cases and two kidney cancer cases. 'Includes two bladder cancer cases and one kidney cancer case.
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drinking water before the beginning and
after the end ofthe consumption ofthe well
water was considered as null. Exposure from
other sources was not taken into account.
Statistical analyses. The study was based
on the case-cohort design described by
Prentice (21) and Barlow (23). In the analysis
of a case-cohort study, the risk set at each
event time (year ofcancer diagnosis) consists
of the case that failed at that particular time
and all members ofthe reference cohort who
were at risk at the time. Members ofthe ref-
erence cohort were weighted in inverse pro-
portion to the sampling fraction (4,590/
144,627). The robust variance matrix was
estimated using SAS/IML (Interactive Matrix
Programming Language; SAS Institute, Cary,
NC). The 95% confidence intervals (CIs)
were calculated from the robust variance esti-
mates andstandarderrors.
Risk ratios (RRs) were estimated using
PHREG (Cox's Multivariable Proportional
Regression Analysis) procedure of SAS, cal-
culated both for continuous and categorical
arsenic exposure (class limits set roughly at
the 50th and 75th percentiles of the refer-
ence cohort). To limit the influence of the
few observations with high levels of arsenic,
we estimated linear models after log-trans-
forming the arsenic exposure indicator.
Cigarette smoking is an established risk fac-
tor for both bladder and kidney cancers
(24,25) and high body mass index (BMI) is
an established risk factor for kidney cancer
(26). The multivariate models of bladder
cancer were adjusted for age, sex, and smok-
ing (never smoked, ex-smoker stopped
smoking before 1970, smoker in the 1970s).
The multivariate models of kidney cancer
were adjusted for age, sex, smoking, and BMI
[< 25, 2 25 weight in kilograms/(height in
meters)2]. Subjects with missing data on
smoking and BMI (Table 3) were included
in the models as a separate category. Use of
analgesics and diuretics in the 1970s and
education were not associatedwith the riskof
bladder or kidney cancers and were therefore
notincluded in the final models.
Results
Arsenicconcentrations in reference wells. The
arsenic concentrations in the wells ofthe ref-
erence cohort ranged from < 0.05 to 64 pg/L
(median 0.14 jig/L; CI, <0.05-4.5; Table 4).
Five percent of the reference cohort had
arsenic concentrations > 5 pg/L, and 1%
(4/275) had consumed well water exceeding
the WHO drinking-water quality guideline
value of 10 pg/L. The median daily dose of
arsenic from well water was 0.2 pg (5th and
95th percentiles were 0.04 and 7 pg, respec-
tively). The cumulative dose before 1980 was
0.8 mg (5th and 95th percentiles were 0.08
and 26 mg, respectively).
Table 2. Demographic description ofthe cases and reference cohort.
Bladder cancer Kidney cancer Reference cohort
(n=61) (n=49) (n=275)
No. %i No. % No. %
Women 11 18 25 51 112 41
Year of birth
1900-1910 14 23 8 16 86 31
1911-1920 22 36 21 43 115 42
1921-1930 25 41 20 41 74 27
Vital status in end of 1995
Alive 32 52 16 33 152 55
Education
Primary school or less 41 67 37 75 169 61
Higher than primary school 1 2 2 4 16 6
Missing 19 31 10 20 90 33
Occupation
Farming 38 62 31 63 179 65
Transport, construction,
service, and administration 20 33 12 24 64 23
Missing 3 5 6 12 32 12
Table3. Characteristics ofthe cases and reference cohort.
Bladder cancer Kidney cancer Reference cohort
(n=61) (n=49) (n= 275)
No. % No. % No. %
Questionnaire respondent
Study person 18 29 7 14 73 27
Spouse 15 25 15 31 39 14
Child, grandchild 9 15 14 29 71 26
Start of using well water
Before 1965 15 25 17 35 72 26
1966-1975 32 52 19 39 156 57
After 1976 14 23 13 26 47 17
Cigarette smoking in the 1970s
Never 18 29 22 45 106 38
Ex-smoker 4 7 7 14 28 10
Smoker 18 29 7 14 35 13
Missing data 21 34 13 26 106 38
Use of diuretics in the 1970s
Never 25 41 15 31 80 29
Ever 12 20 12 24 72 26
Missing data 24 39 22 45 123 45
Use of painkillers with phenacetin or
phenylbutazon in the 1970s
Never 12 20 7 14 39 14
Ever 3 5 5 10 25 9
Missing data 46 75 37 75 211 77
BMI(kg/M2) in the end ofthe 1970s
<25 25 41 13 26 68 25
>25(overweight) 14 23 21 43 97 35
Missingdata 22 36 15 31 110 40
BMI, body mass index.
Table4. Arsenic exposure among cases and the reference cohort.
Bladder cancer Kidney cancer Reference cohort
(n=61) (n=49) (n= 275)
Percentile Percentile Percentile
50th 75th 95th 50th 75th 95th 50th 75th 95th
Arsenic concentration in 0.1 0.6 3.0 0.1 0.6 1.8 0.1 0.5 4.5
well water (pg/L)
Daily dose of arsenic from 0.2 0.9 4.8 0.2 0.9 3.0 0.2 0.7 7.2
well water(pg)
Cumulative dose of arsenic from 0.6 2.6 28 0.7 2.8 24 0.8 2.6 26
well water before 1980(mg)
Duration ofwellusebefore 9 15 24 9 17 25 10 15 23
1980 (years)
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Ninety-four percent of the drilled wells
were still in use in 1996. The depth of the
well (median 42 m, range 5-172 m) did not
correlate (Pearson correlation coefficient
0.06) with the (log-transformed) arsenic
concentrations. Water treatment was rare: it
was reported for only 11 wells, most fre-
quentlyfor iron removal.
Characteristics ofcases versus controls.
The study population was a demographically
rather homogeneous group ofpeople with a
mainly agricultural background (Table 2).
The residence locations of cancer cases and
referents did not differ systematically (Figure
1). Residential mobility was remarkably low;
71% of those alive in 1996 still lived in the
same place where they had lived in 1967.
Cigerette smoking in the 1970s was more
common among the cancer cases than among
the reference cohort; the association between
smoking and bladder cancer was statistically
significant (Tables 3 and 5).
Arsenic and bladder cancer. We
observed an increasing trend for arsenic con-
centrations in drinking water and the daily
dose ofarsenic with shorter latency, but not
with longer latency (Table 6). The point
estimate for arsenic concentration > 0.5 jig/L
was statistically significantly elevated. The
association between arsenic exposure and
bladder cancer tended to be stronger among
thosewho smoked in the 1970s (Table 7).
Arsenicandkidney cancer. We found no
evidence for an association between arsenic
concentration, daily dose, or cumulative
dose and the riskofkidney cancer (Table 8).
Discussion
High concentrations ofarsenic in drilled wells
were previously detected in southwestern
Finland (19,22), and geochemical surveys
(20) suggest high arsenic concentrations in
other areas as well. However, our findings
indicate that substantial arsenic exposure
through drilled well water in Finland is
uncommon. Assuming that the entire arsenic
dose from drinking water was in inorganic
form, the median dose of inorganic arsenic
from well water in the reference cohort was
approximately 0.2 pg/day. This is similar to
the estimated dose from drinkingwater in the
Czech Republic (2), but lower than that esti-
mated in theUnitedStates (4pg/day) (27).
We have previously shown that the
steady-state current arsenic exposure can be
adequately estimated by asking subjects
about daily drinking-water consumption at
home (19). In the present study, however,
we were interested in the water consump-
tion in the 1970s, which is more prone to
misclassification and affected by recall bias.
The earlier arsenic concentrations were con-
sidered to be the same as they were at the
time of the sampling, which may introduce
errors. No published data on annual varia-
tions ofarsenic concentrations in well water
in Finland were available, but the concen-
trations may fluctuate depending on the
water catchment basin of the well (i.e., the
level of groundwater). Some studies have,
however, reported that arsenic concentra-
tions in wells in arsenic-rich areas remain
relatively constant for decades (11,12).
The calculation of cumulative dose is
more sensitive to errors than daily dose or
concentration. The year of beginning of
well-water use may not have been recalled
adequately, and an error in the duration of
well-water use has a significant influence on
the amount ofcumulative dose. The arsenic
concentrations in drinking water other than
those measured from drilled wells were con-
sidered zero. This may introduce misclassifi-
cation in the cumulative dose, especially
when arsenic concentrations in drilled wells
were as low as in other sources of drinking
water. This misclassification, however, is
likely to be nondifferential.
The arsenic doses found in previous stud-
ies (5-12) on arsenic exposure and cancer in
urinary organs were much higher than those
found in this study. In the present study, we
used individual arsenic exposure variables
instead ofarea-based measures used in most
previous studies. Studies in Taiwan have sug-
gested that cancers of the bladder, kidney,
lung, liver, skin, andpossibly some other sites
are associated with drinking-water arsenic
concentrations ranging from 10 to 1,800
pg/L (5-8,28) and from 350 to 1,140 pg/L
(9). Furthermore, ingested arsenic exposure
has been associated with the increased risk of
cancers in urinary organs in Argentina,
Japan, and Chile. The lowest cut points of
the categorical arsenic concentrations were
40 ,ug/L inArgentina (12,13) and 50 pg/L in
Japan (14,15). In Chile, the regional average
arsenic concentrations in drinking water
ranged from 43 to 570 pg/L (16). The only
earlier nonecological study on bladder cancer
risk and lower arsenic concentrations (from
0.5 to 180 jig/L) in drinking water in the
United States did not show a clear associa-
tion (12). A follow-up study among English
patients showed that orally administered
arsenic medication with substantially higher
doses was associated with an increase in blad-
der cancermortality (29).
We found some suggestion of an
increased bladder cancer risk associated with
low arsenic exposure levels in the present
study. The risk estimates for bladder cancer
and arsenic concentration, as well as daily
dose from 2 to 9 years before the cancerdiag-
nosis, were above unity, and there was some
indication of a dose response. A statistically
significantly elevated risk of bladder cancer
was observed for arsenic concentrations >
0.5 ,pg/L. Exposures earlier than 10 years
Table 5. Age- and sex-adjusted univariate risk
ratios (RR)forcancer ofthe urinary organs and 95%
confidence intervals(Cl)forconfounderVariables.
n RR Cl
Bladder cancer
Cigarette smoking in the 1970s
Never 18 1
Ex-smoker 4 0.44 0.13-1.49
Smoker 18 2.32 1.02-5.30
Missing data 21 1.04 0.50-2.20
Kidney cancer
Cigarette smoking in the 1970s
Never 22 1
Ex-smoker 7 1.49 0.53-4.24
Smoker 7 1.52 0.52-4.41
Missing data 13 0.73 0.35-1.55
BMI (kg/M2) in the
end ofthe 1970s
<25 13 1
. 25(overweight) 21 1.85 0.55-2.56
Missing data 15 0.81 0.36-1.83
Table 6. Age-, sex-, and smoking-adjusted risk ratios (RR) and 95% confidence intervals (Cl) of bladder
cancer inthe Finnish case-cohortstudy on arsenic exposurefrom well water.
Shorter latencya Longer latencyb
Exposure No. RR Cl No. RR Cl
Concentration of arsenic in water(pg/L)
< 0.1 23 1 26 1
0.1-0.5 19 1.53 0.75-3.09 18 0.81 0.41-1.63
>0.5 19 2.44 1.11-5.37 17 1.51 0.67-3.38
(log) continuousc 61 1.37 0.95-1.96 61 0.96 0.59-1.55
Daily dose of arsenic (pg/day)
<0.2 29 1 32 1
0.2-1.0 17 1.34 0.66-2.69 16 0.76 0.38-1.52
> 1.0 15 1.84 0.84-4.03 13 1.07 0.48-2.38
(log) continuousc 61 1.34 0.95-1.90 61 0.91 0.55-1.48
Cumulative dose of arsenic(mg)
<0.5 16 1 27 1
0.5-2.0 20 1.61 0.74-3.54 21 0.81 0.39-1.69
> 2.0 25 1.50 0.71-3.15 13 0.53 0.25-1.10
(log) continuousc 61 0.92 0.57-1.47 61 0.78 0.51-1.20
"Exposure in the third to ninth calendar years prior to the cancer diagnosis. bExposure in the tenth calendar year and
earlier priortothe cancerdiagnosis. cResiltfromthe model using log-transformed exposure values.
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before cancer diagnoses did not show an
association with bladder cancer risk. Hence,
relatively recent arsenic exposure appears to
be more relevant for bladder cancer risk.
This is in concordance with the hypothesis
that arsenic compounds act as promoters
and/or co-carcinogens in the late stage of
carcinogenesis (30-32.
Cigarette smokingin the 1970swas more
common among bladder cancer cases than
among referents; this is in agreement with
previous studieswhich reported that smoking
is associated with bladder cancer (25). In
addition, there was some suggestion ofa syn-
ergistic effect ofarsenic and smoking (Table
7). This finding is consistent with earlier
studies in which elevated arsenic exposure
tended to increase the bladder cancer risk
(9,17) among smokers. Experimental studies
also suggest that arsenic compounds pro-
mote the carcinogenicity and genotoxicity of
the known carcinogens and genotoxic com-
pounds (31-33).
In this study, no association was
observed between kidney cancer and arsenic
exposure from drinkingwater. In earlier epi-
demiologic studies, an association between
arsenic exposure and kidney cancer was
somewhat weaker than the association to
bladder cancer (6-8,10,11,13,16).
It is difficult to compare the cancer risks
between various studies because arsenic expo-
sure has been expressed in different ways and
because the extension and duration ofarsenic
exposure in these studies are different. The
differences in the effect estimates in the stud-
ies may also be due to the differences in the
possible misclassification ofarsenic exposure,
other sources ofarsenic or other carcinogens,
genetic background, health status, or nutri-
tional status. Most of the previous studies
have had a cancer mortality as an end point.
The participants in this studywereolderthan
persons in previous epidemiologic studies.
Applying the results for cancer mortality
obtained by Smith et al. (3) from Taiwanese
data, the highest exposure categories in the
present study population (median arsenic
concentration 1.99 pg/L) would have a rela-
tive risk for bladder cancer of 1.01 in men
and 1.03 in women. Hence, the present
results, relative risk > 2, are higher than
expected and raise a concern of the possible
roleofbias orchance.
Nutritional factors may modify the
metabolism and possibly carcinogenicity of
arsenic. Selenium is an important anticar-
cinogen (34), and it has been suggested to
reduce the toxicity of arsenic (35) and to
inhibit the methylation ofinorganic arsenic
in vitro (36). Therefore, deficiency ofseleni-
um mayincrease the cancer riskofarsenic. In
Finland, the dailyintake ofselenium (average
30 jig) (37) was below the recommended
50-200 pg (38) before selenium supplemen-
tation in fertilizers started in 1985.
The crude risk ratios ofarsenic exposure
and bladder cancer increased only slightly
after adjustment for smoking. This suggests
that, although the proportion of missing
data on smoking was large, the results are
probably not confounded by smoking. We
believe that serious differential misclassifica-
tion is unlikely in the present study. There
were no differences between cases and non-
cases in thesampling oranalyzing procedure.
Furthermore, there were no differences in
the demographic parameters of the eligible
and the final study populations. It has previ-
ously been shown that relatives are able to
provide rather reliable information on smok-
ing and other major demographic and
lifestyle factors (39-41).
Our results show that high arsenic levels
in Finnish drilled wells used in the 1970s
were uncommon and exposure through
drinking water was low. We found no statis-
tically significant association between arsenic
and risk ofkidney cancer. However, consis-
tent with earlier studies, there was some evi-
dence for an increased risk ofbladder cancer
associated with arsenic exposure 2-9 years
before the diagnosis and some suggestion ofa
synergistic effect between arsenic and smok-
ing. Due to lowexposure levels in the present
study, the positive association between
arsenic exposure and risk of bladder cancer
was not expected, and the role of bias and
chance needs to becarefulllyconsidered.
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(CIs) ofthe Finnish case-cohort studyon arsenic exposurethrough well water.
Shorterlatency" Longerlatencyb
Exposure No. RR Cl No. RR Cl
Concentration ofarsenic in water(pg/L)
<0.1 23 1 25 1
0.1-0.5 12 0.78 0.37-1.66 9 0.33 0.14-0.77
.0.5 14 1.49 0.67-3.31 15 1.07 0.46-2.52
(log)continuousc 49 1.16 0.80-1.69 49 0.72 0.38-1.36
Dailydose ofarsenic (pg/day)
<0.2 26 1 27 1
0.2-1.0 13 1.08 0.52-2.25 11 0.55 0.25-1.21
.1.0 10 1.21 0.52-2.82 11 0.94 0.39-2.27
(log)continuousc 49 1.10 0.77-1.58 49 0.59 0.28-1.23
Cumulative dose ofarsenic (mg)
<0.5 18 1 24 1
0.5-2.0 12 0.74 0.33-1.68 11 0.36 0.16-0.81
22.0 19 0.80 0.42-1.86 11 0.47 0.21-1.04
(log)continuousc 49 0.59 0.28-1.23 49 0.76 0.44-1.30
&Exposure in the third to ninth calendar years prior to the cancer diagnosis. bExposure in the tenth calendar year and
earlier priortothe cancer diagnosis. 0Resultfromthe model using log-transformed exposure values.
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